Abstract:Despite being rare cancers, ovarian cancer rank as the fifth leading cause of cancer mortalities in women in the United States. Most patients are detected late, with most patients diagnosed in Stages 3 and 4. While patients often initially respond to standard of care chemotherapy, which includes platinum-based chemotherapy such as cisplatin and carboplatin, they recur with resistant phenotypes. While a large effort has characterized mechanisms of resistance to platinum-based chemotherapy, it is still challenging to identify these patients and identify more promising therapies. While the field understands that a quiescent, stem cell-like state can serve as an intermediate from which chemoresistant recurrences can arise, the epigenetics of this state are less well understood. In fact, we do know that embryonic and pluripotent stem cells differ significantly in enhancers and other epigenetic features that contribute significantly to their phenotypes. We performed histone post-translational modifications by CUT&Tag, as well as ATACseq and RNA-seq, on four isogenic cell line models of cisplatin resistance. We show that these models are resistant to both cisplatin and carboplatin. While we see paradoxical quiescent cell markers in these isogenic lines, we have characterized differential features of their epigenetics that may contribute to the resistant phenotype. We are continuing to explore transcription factors that may drive this resistance. We are also examining super-enhancers that are altered between chemo-sensitive and -resistant cell lines. Similarly, we have examined whether inhibitors of components of super-enhancers may be a viable therapeutic option for platinum-resistant high-grade serous ovarian cancer patients. We see moderate synergy between triptolide (targets TFIIH subunit XPB1) and JQ-1 (targets BRD4) with cisplatin in resistant models. Together, we hope our studies can contribute to the knowledge of how epigenetic features might contribute and be targets for chemoresistance in ovarian cancer. Citation Format: Kristin Adams, Ryan Moreno, Jae-Rim Wendt, Josie Wood, Avtar Roopra, Jessica D. Lang. A multi-omic analysis to identify epigenetic drivers of platinum-resistance in high-grade serous ovarian carcinoma models [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2) nr B003.

Discovery of Natural Ursane-type SENP1 Inhibitors and the Platinum Resistance Reversal Activity Against Human Ovarian Cancer Cells: A Structure–Activity Relationship Study

GANT61 Elevates Chemosensitivity to Cisplatin Through Regulating the Hedgehog, AMPK and Camp Pathways in Ovarian Cancer

Nanoengineered Gallium Ion Incorporated Formulation for Safe and Efficient Reversal of PARP Inhibition and Platinum Resistance in Ovarian Cancer.

Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells

Identification of Three Potential Prognostic Genes in Platinum-Resistant Ovarian Cancer Via Integrated Bioinformatics Analysis.

Chemistry of bioluminescence

Discovery and radiosensitization research of ursolic acid derivatives as SENP1 inhibitors

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance

Mitochondrial and cytosolic one-carbon metabolism is a targetable metabolic vulnerability in cisplatin-resistant ovarian cancer

Proteasome Inhibitor Ysy01a Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells

Discovery of the Next-Generation Platinum-Based Anticancer Agents for Combating Oxaliplatin-Induced Drug Resistance

Oxyresveratrol Enhances the Anti-Cancer Effect of Cisplatin against Epithelial Ovarian Cancer Cells through Suppressing the Activation of Protein Kinase B (AKT)

The Nrf2/PGC1α Pathway Regulates Antioxidant and Proteasomal Activity to Alter Cisplatin Sensitivity in Ovarian Cancer

Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity via Suppressing NOTCH2 Expression and Stemness

Abstract B003: A multi-omic analysis to identify epigenetic drivers of platinum-resistance in high-grade serous ovarian carcinoma models

Unlocking the Potential of Organopalladium Complexes for High-Grade Serous Ovarian Cancer Therapy

Can a collaborative network environment enhance essay-writing processes?

Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

Construction of plasmids and expression in Escherichia coli of enzymatically active fusion proteins containing the heme-domain of a P450 linked to NADPH-P450 reductase.